PWMG
CTKB icon

Prestige Wealth Management Group’s Cytek Biosciences CTKB Stock Holding History

Prestige Wealth Management Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06K Hold
240
– – ﹤0.01% 890
2026
Q1 		$1.05K Hold
240
– – ﹤0.01% 853
2025
Q4 		$1.21K Hold
240
– – ﹤0.01% 845
2025
Q3 		$833 Buy
+240
New +$901 ﹤0.01% 879

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prestige Wealth Management Group's CTKB Position: Q2 2026 in Review

Prestige Wealth Management Group held its Cytek Biosciences (CTKB) position steady in Q2 2026 at 240 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #890.

Prestige Wealth Management Group first reported a position in CTKB in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.21K in Q4 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Prestige Wealth Management Group held 240 shares of Cytek Biosciences worth $1.06K as of Q2 2026.
  • Prestige Wealth Management Group left its Cytek Biosciences share count unchanged in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #890 holding.
  • Prestige Wealth Management Group first reported a position in Cytek Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Prestige Wealth Management Group's Cytek Biosciences position peaked at $1.21K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.